PRS4035
Anti-DRAM (ab2) antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
别名:
Anti-Damage-regulated autophagy modulator
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA (i), IF, IHC, WB
Citations:
2
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
predicted mol wt 26 kDa
species reactivity
mouse, rat, human
technique(s)
immunofluorescence: suitable, immunohistochemistry: suitable, indirect ELISA: suitable, western blot: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... DRAM(55332)
Immunogen
a 16 amino acid peptide from near the amino-terminus of human DRAM.
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Physical form
Solution in phosphate buffered saline containing 0.02% sodium azide
Other Notes
The action of this antibody can be blocked using blocking peptide SBP4035.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
此项目有
André Wirries et al.
Oncotarget, 9(68), 32997-33010 (2018-09-27)
Osteosarcoma is an aggressive cancer with a poor long term prognosis. Neo-adjuvant poly-chemotherapy followed by surgical resection remains the standard treatment, which is restricted by multi-drug resistance. If first-line therapy fails, disease control and patient survival rate drop dramatically. We
Brandon J Metge et al.
Scientific reports, 5, 11995-11995 (2015-07-07)
We have previously reported that expression of NMI (N-myc and STAT interactor) is compromised in invasive breast cancers. We also demonstrated that loss of NMI expression promotes epithelial-mesenchymal-transition and results in enhanced invasive ability of breast cancer cells. Additionally we
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SBP4035-0.05MG | 04061832163000 |
| PRS4035-100UG | 04061832179025 |